

# Andrew J Cowan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9912241/publications.pdf>

Version: 2024-02-01

28  
papers

1,547  
citations

759233

12  
h-index

677142

22  
g-index

29  
all docs

29  
docs citations

29  
times ranked

1826  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Diagnosis and Management of Multiple Myeloma. JAMA - Journal of the American Medical Association, 2022, 327, 464.  | 7.4 | 308       |
| 2  | Prolonged Lenalidomide Therapy Does Not Impact Autologous Peripheral Blood Stem Cell Mobilization and Collection in Multiple Myeloma Patients: A Single-Center Retrospective Analysis. Transplantation and Cellular Therapy, 2021, 27, 661.e1-661.e6.                    | 1.2 | 5         |
| 3  | Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study. Lancet Haematology, the, 2021, 8, e562-e571.                                | 4.6 | 28        |
| 4  | Phase I study protocol: NKTR-255 as monotherapy or combined with daratumumab or rituximab in hematologic malignancies. Future Oncology, 2021, 17, 3549-3560.   | 2.4 | 10        |
| 5  | Stem Cell Collection with Daratumumab (DARA)-Based Regimens in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) in the Griffin and Master Studies. Blood, 2021, 138, 2852-2852.  | 1.4 | 7         |
| 6  | Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 24 Months of Maintenance. Blood, 2021, 138, 79-79.                       | 1.4 | 20        |
| 7  | Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): A Subgroup Analysis of Griffin. Blood, 2021, 138, 2723-2723.   | 1.4 | 3         |
| 8  | The Global State of Hematopoietic Cell Transplantation for Multiple Myeloma: An Analysis of the Worldwide Network of Blood and Marrow Transplantation Database and the Global Burden of Disease Study. Biology of Blood and Marrow Transplantation, 2020, 26, 2372-2377. | 2.0 | 19        |
| 9  | Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood, 2020, 136, 936-945.   | 1.4 | 436       |
| 10 | Standardizing Chemotherapy Regimen Nomenclature: A Proposal and Evaluation of the HemOnc and National Cancer Institute Thesaurus Regimen Content. JCO Clinical Cancer Informatics, 2020, 4, 60-70.   | 2.1 | 9         |
| 11 | Pembrolizumab with Râ€œCHOP in previously untreated diffuse large Bâ€œcell lymphoma: potential for biomarker driven therapy. British Journal of Haematology, 2020, 189, 1119-1126.   | 2.5 | 69        |
| 12 | KRD-PACE Mobilization for Multiple Myeloma Patients With Significant Residual Disease Before Autologous Stem-Cell Transplantation. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 602-609.   | 0.4 | 5         |
| 13 | Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 12 Months of Maintenance Therapy. Blood, 2020, 136, 45-46.                     | 1.4 | 19        |
| 14 | Intensity of End of Life Care for Hematologic Malignancy Patients in Western Washington, United States and Alberta, Canada. Blood, 2020, 136, 21-21.   | 1.4 | 0         |
| 15 | Comparison of Outcomes and Utilization of Therapy in Multiple Myeloma Patients in the USA and Alberta, Canada. Blood, 2020, 136, 20-21.  | 1.4 | 0         |
| 16 | Burden of Multiple Myeloma in Taiwanâ€œReply. JAMA Oncology, 2019, 5, 116.   | 7.1 | 0         |
| 17 | Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Griffin Study Update. Blood, 2019, 134, 691-691.                       | 1.4 | 37        |
| 18 | High Throughput Drug Synergy Testing in a Clinical Trial of Panobinostat, Carfilzomib, Dexamethasone to Define Response Biomarkers for Relapsed/Refractory Multiple Myeloma. Blood, 2019, 134, 1902-1902.  | 1.4 | 3         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Circulating Plasma Cells at the Time of Collection of Autologous PBSC for Transplant in Multiple Myeloma Patients is a Negative Prognostic Factor Even in the Age of Post-Transplant Maintenance Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1386-1391.  | 2.0 | 17        |
| 20 | Plasma cell diseases and organ transplant: A comprehensive review. <i>American Journal of Transplantation</i> , 2018, 18, 1046-1058.   | 4.7 | 9         |
| 21 | Global Burden of Multiple Myeloma. <i>JAMA Oncology</i> , 2018, 4, 1221.   | 7.1 | 398       |
| 22 | Fully Human Bcma Targeted Chimeric Antigen Receptor T Cells Administered in a Defined Composition Demonstrate Potency at Low Doses in Advanced Stage High Risk Multiple Myeloma. <i>Blood</i> , 2018, 132, 1011-1011.  | 1.4 | 91        |
| 23 | Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> . 2016, 23, 254-259. | 3.0 | 6         |
| 24 | Safety and Activity of Brentuximab Vedotin (BV) Plus Ifosfamide, Carboplatin, and Etoposide (ICE) for Relapsed/Refractory (Rel/Ref) Classical Hodgkin Lymphoma (cHL): Initial Results of a Phase I/II Trial. <i>Blood</i> , 2016, 128, 1834-1834.  | 1.4 | 42        |
| 25 | Real World Utilization and Practice Patterns of Dose-Adjusted EPOCH for Aggressive B-Cell Lymphomas 2005-2015: Impact of Growth Factor Choice and Resultant Achieved Dose Level. <i>Blood</i> , 2016, 128, 3577-3577.  | 1.4 | 0         |
| 26 | Frequency of Amyloid Subtyping Among Patients with Immunoglobulin Light-Chain Amyloidosis Referred for High-Dose Chemotherapy and Autologous Stem Cell Transplant. <i>Blood</i> , 2016, 128, 5601-5601.  | 1.4 | 0         |
| 27 | Management of Acute Myeloid Leukemia in the Intensive Care Setting. <i>Journal of Intensive Care Medicine</i> , 2015, 30, 375-384.   | 2.8 | 6         |
| 28 | Results of a Phase I-II Study of Fenretinide and Rituximab for Patients with B-Cell Lymphomas. <i>Blood</i> , 2015, 126, 2728-2728.  | 1.4 | 0         |